qpgraph. Accession numbers: Mitochondrial genome sequences are deposited in GenBank (KX353757-KX353761 The ongoing Zika virus (ZIKV) outbreak is linked to severe neurological disorders. ZIKV relies on its NS2B/NS3 protease for polyprotein processing; hence, this enzyme is an attractive drug target. The 2.7 angstrom crystal structure of ZIKV protease in complex with a peptidomimetic boronic acid inhibitor reveals a cyclic diester between the boronic acid and glycerol. The P2 4-aminomethylphenylalanine moiety of the inhibitor forms a salt-bridge with the nonconserved Asp 83 of NS2B; ion-pairing between Asp 83 and the P2 residue of the substrate likely accounts for the enzyme's high catalytic efficiency. The unusual dimer of the ZIKV protease:inhibitor complex seen in the crystal may provide a model for assemblies formed at high local concentrations of protease at the endoplasmatic reticulum membrane, the site of polyprotein processing. P reviously considered a rare and mild pathogen for humans (1), Zika virus (ZIKV) infection has recently been found to be responsible for neurological disorders in a substantial portion of patients. The infection can trigger Guillain-Barré syndrome (2) , and prenatal ZIKV infection is responsible for a dramatically increased number of microcephaly cases in fetuses and newborn children (3) . The World Health Organization (WHO) recently declared the association of ZIKV infection with these neurological disorders a Public Health Emergency of International Concern (4). There are no vaccines or antiviral drugs available for protection from or treatment of ZIKV infection.
ZIKV is a member of the genus Flavivirus in the Flaviviridae family of RNA viruses. Its ∼10.7-kb single-stranded RNA genome of positive polarity encodes a single polyprotein, which, by analogy to other flaviviruses, is assumed to be cleaved by host-cell proteases (signalase and furin) and the viral NS2B/NS3 protease into three structural (C, prM/M, and E) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) ( fig. S1 ). Similar to other flavivirus proteases, such as those of dengue virus (DENV) and West Nile virus (WNV), the mature form of ZIKV protease consists of the N-terminal domain of NS3, which carries the catalytic triad Ser 135 -His
51
-Asp 75 , and the membrane-bound NS2B (a sequence alignment is available in fig.  S2 ). Crystallization of this complex has not been successful so far for any flavivirus protease, but it has been shown that a construct comprising~40 hydrophilic residues of NS2B and~185 residues of NS3, covalently linked via a Gly 4 -Ser-Gly 4 sequence, displays strong peptidolytic activity (5) . Crystal structures of the free form of this protease construct ("NS2B-NS3 pro ") usually reveal an "open conformation" featuring a well-ordered NS3 pro core and a flexible NS2B part that shows only limited interaction with NS3 pro , whereas inhibitor (and presumably substrate) binding induces a pronounced conformational change of NS2B yielding a more compact, "closed" form (6, 7).
We expressed in Escherichia coli a DNA construct corresponding to the NS2B-NS3 pro -coding region of the Brazilian ZIKV isolate BeH823339 (GenBank accession number KU729217.2) (8). This construct codes for residues 49 to 95 of ZIKV NS2B, the C terminus of which is covalently linked via Gly 4 -Ser-Gly 4 to the N terminus of NS3 (residues 1 to 170). The recombinant enzyme obtained is a mixture of monomer, disulfidelinked dimer (here designated "SS-dimer") andto a lesser extent-higher oligomers ( fig. S3) pro are hyperactive against the standard flavivirus protease substrate benzoyl-norleucinelysine-lysine-arginine 7-amino-4-methylcoumarine (Bz-Nle-Lys-Lys-Arg-AMC), with a very low Michaelis constant (K m ) and a specific catalytic efficiency (k cat /K m ) more than 20 times higher than for the WNV enzyme (Table 1) .
In order to elucidate the molecular basis of this hyperactivity, and to provide a starting point for structure-based drug design efforts, we have crystallized ZIKV NS2B-NS3 pro in the closed form and determined its x-ray structure at 2.7 Å resolution. Containing two molecules ("A" and "B") per asymmetric unit of the crystal, the structure reveals the same chymotrypsin-like fold for the NS3 pro domain as seen previously for other flavivirus proteases, with the NS2B polypeptide wrapped around the NS3 pro . The interaction between the two is stabilized by hydrogen bonds between b-strands b1 and AI, b2 and BIIa, as well as b3 and BIIb of NS2B and NS3 pro , respectively (Fig. 1A) . The root mean square deviations between the ZIKV NS2B-NS3 pro complex and tetrapeptide aldehyde complexes of WNV and DENV-3 proteases are 0.9 to 1.1 Å [for main-chain atoms; Protein Data Bank (PDB) codes 2FP7 and 3U1I (6, 9)]. The capped dipeptide boronic acid compound cn-716 ( Fig. 1C ) was used to obtain the closed conformation of the protease. We found this compound to reversibly inhibit ZIKV NS2B-NS3 pro with half maximal inhibitory concentration (IC 50 ) = 0.25 ± 0.02 mM and inhibition constant (K i ) = 0.040 ± 0.006 mM (in the presence of 20% glycerol) ( fig. S4 ). In the structure of the complex, the boron atom is covalently linked to the side-chain Og of the catalytic Ser 135 (Fig. 1 , B and D to F). The structure also reveals that the boronic acid moiety forms a cyclic diester with glycerol, which was continuously present in our enzyme preparation during purification and crystallization, as well as cryoprotection of crystals. Boronic acids tend to form esters with diols and triols, especially if five-or six-membered rings can be formed (10) . Our F obs -F calc (observed and calculated structure-factor amplitudes, respectively) difference density indicates that a six-membered ring has been formed by reaction of the boronic acid with the terminal hydroxyl groups of glycerol (Fig. 1, B and D to F) . The six-membered ring fits neatly into the S1′ pocket of the enzyme (Fig. 1B) , a site so far rarely addressed by synthetic flavivirus protease inhibitors. In the absence of glycerol, the IC 50 for the boronic acid inhibitor was nearly unchanged (0.20 ± 0.02 mM), but through ester formation with larger, more hydrophobic diols or triols, a prodrug might be obtained that will traverse the cellular membrane more readily than will free boronic acid derivatives.
Because of the ring closure, the tetrahedral geometry of the boron is somewhat distorted. In molecule A, the six-membered ring assumes a boat-like conformation, with the middle hydroxyl group (O2) of glycerol in an axial position and donating an intramolecular hydrogen bond to the main-chain oxygen of the P2 residue of the inhibitor (Fig. 1E) . In molecule B, the six-membered ring adopts a somewhat twisted half-chair conformation, and the central hydroxyl group, also in an axial position, donates a hydrogen bond to the carbonyl oxygen of Val 36 (Fig. 1F) . In molecule A, the two ring oxygens (O1 and O3) accept H-bonds respectively from the amide of Gly
133
(from the oxyanion hole) and from the catalytic His 51 , whereas the latter interaction is missing in molecule B. These differences between the two inhibitor molecules in the asymmetric unit of the crystal reflect the conformational variability of the cyclic boronates (10) . (Table 1 ). The Asp residue in this position provides an at least partial explanation for the lower K m and hence the much higher k cat /K m of ZIKV protease as compared with the WNV and DENV enzymes (Table 1) . DENV NS2B/NS3 protease has been shown to counteract the type-I interferon response via digesting the stimulator of inferon genes (STING) in human dendritic cells (DCs) (11) . Because ZIKV also permissively infects human DCs (12), we speculate that an increased catalytic activity of ZIKV NS2B/NS3 pro could cause more efficient cleaveage of STING, leading to an enhanced suppression of the host innate immunity.
In the crystal, ZIKV NS2B-NS3 pro forms an unusual dimer with noncrystallographic, quasitwofold symmetry ( Fig. 2A) that has not been seen with other flavivirus proteases. This tight dimer has to be distinguished from the labile SSdimers seen in solution. In the tight dimer, the substrate-binding sites of the two monomers, along with the bound inhibitor, face each other (Fig. 2B) . The dimer has openings at both sides, which upon some "breathing" would allow access of substrate to the two active sites located at the center (Fig. 2A) . The tight dimer in the asymmetric unit of the crystal is connected to neighboring dimers through two labile disulfide bonds linking Cys 143 of monomer A to the same residue of monomer B in a symmetry-related dimer, and vice versa, giving rise to disulfide-mediated polymers of tight dimers (Cys 143 is indicated in Fig.  2A ). This disulfide bond is responsible for the formation of the "SS-dimer" apparent in the SDS-polyacrylamide gel electrophoresis ( fig. S3) . After a few seconds of the crystal in the x-ray beam, this exposed disulfide appears to be reduced as a consequence of irradiation, although the presence of the disulfide seems to be essential for crystallization of the ZIKV NS2B-NS3 Formation of the tight dimer in the asymmetric unit buries~1240 Å 2 of the surface of each of the two monomers, and the shape complementarity (Sc) index (13) is 0.64 [for a large set of well-characterized homodimeric proteins, the mean Sc was 0.69 ± 0.07 (14) ]. If we include the two inhibitor molecules in the calculation,~1500 Å 2 of molecular surface are buried per monomer. Both the large surface area buried and the shape complementarity indicate that dimer formation is likely of biological relevance. Although we failed to observe this dimer in solutions of the ZIKV NS2B-NS3
pro complex with cn-716 up to a concentration of 133 mM, we detected it by means of electrospray ionization mass spectrometry in the presence but not in the absence of the boronic acid inhibitor (fig. S6 ). The structure suggests that the closed form of the enzyme has the potential of forming well-defined dimers at higher concentrations as they may occur (and are perhaps promoted by the membrane-embedded parts of NS2B, which are lacking in the present structure) at the endoplasmic reticulum membrane, where polyprotein processing and viral replication take place. Peptide boronic acids have previously been tested as drugs, and the proteasome inhibitor bortezomib (Velcade) has been approved for the treatment of multiple myelomas (15) . A tetrapeptideboronic acid was reported as a potent inhibitor of the DENV-2 NS2B-NS3 pro but not studied further (16) . Peptide boronic acids are usually not cytotoxic to Huh7 cells, which is what we observed with compound cn-716 ( fig. S7) . The structure presented here forms a good starting point for the design of more specific anti-ZIKV drugs. fig. S5 . 
